牛心包主动脉瓣生物瓣膜两年安全性、疗效与血流动力学分析
PERIcardial SurGical AOrtic Valve ReplacemeNT关键试验纳入1273例有症状的中重度主动脉瓣狭窄或反流患者,1110例接受Avalus牛心包瓣膜植入。2年随访显示临床安全性和疗效良好,平均跨瓣压差与现有牛心包瓣膜相当,中度至重度患者-人工瓣膜不匹配无临床影响。
要点
- Avalus瓣膜2年临床安全性和疗效良好,瓣膜相关死亡率为0.42%/患者年。
- 2年平均跨瓣压差13.4±5.0 mmHg,有效瓣口面积1.5±0.37 cm²。
- 中度与重度患者-人工瓣膜不匹配分别占43.5%和34.8%,但2年时无临床影响。
核心结论
- Avalus牛心包瓣膜在2年时表现出良好的临床和安全性结局。
- 血流动力学性能显示平均跨瓣压差与现有牛心包主动脉瓣相当。
- 中度至重度患者-人工瓣膜不匹配在2年时无临床影响。
研究设计与样本
- PERIcardial SurGical AOrtic Valve ReplacemeNT关键试验,在加拿大、欧洲和美国中心纳入有症状中重度主动脉瓣狭窄或反流患者。
- 共纳入1273例患者,1110例接受植入,分析时604例完成2年随访。
主要发现
- 植入患者平均年龄70.2±8.9岁,833例(75.0%)为男性,STS死亡风险2.0%±1.4%。
- 线性化晚期事件率:全因死亡2.68%、瓣膜相关死亡0.42%、瓣膜血栓0.05%、心内膜炎0.94%、血栓栓塞1.68%、所有出血2.94%、大出血1.99%、所有瓣周漏0.26%、主要瓣周漏0.05%(每患者年)。
- 2年平均主动脉瓣压差13.4±5.0 mmHg,有效瓣口面积1.5±0.37 cm²。
- 2年时中度与重度患者-人工瓣膜不匹配分别占43.5%和34.8%。
- NYHA心功能分级较基线改善:中度不匹配组73.0%,重度不匹配组74.1%。
临床怎么用
- Avalus瓣膜可作为主动脉瓣置换的选项,2年血流动力学表现与现有牛心包瓣膜相当。
- 术后2年内中度至重度患者-人工瓣膜不匹配未显示临床影响,但仍需进一步随访评估中长期结局。
局限性
- 需要进一步随访以评估中期至长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The study objectives were to evaluate the safety, efficacy, and hemodynamic performance of a novel stented bovine pericardial aortic valve bioprosthesis 2 years after implantation. METHODS: The PERIcardial SurGical AOrtic Valve ReplacemeNT Pivotal Trial enrolled patients with symptomatic moderate/severe aortic stenosis or regurgitation at centers in Canada, Europe, and the United States. We report the outcomes and hemodynamic performance in patients with up to 2 years of follow-up. RESULTS: A total of 1273 patients were enrolled, and 1110 underwent implantation. Among patients undergoing implantation, the mean age was 70.2 ± 8.9 years; 833 (75.0%) were male. Risk of mortality (Society of Thoracic Surgeons) was 2.0% ± 1.4%. At the time of analysis, 604 patients had completed the 2-year follow-up visit. Linearized late event rates were as follows: all death, 2.68%; valve-related death, 0.42%; valve thrombosis, 0.05%; endocarditis, 0.94%; thromboembolism, 1.68%; all hemorrhage, 2.94%; major hemorrhage, 1.99%; all paravalvular leak, 0.26%; and major paravalvular leak, 0.05% per patient-year. Mean 2-year aortic gradient and effective orifice area were 13.4 ± 5.0 mm Hg and 1.5 ± 0.37 cm2, respectively. Moderate and severe prosthesis-patient mismatch were observed in 43.5% and 34.8% of patients at 2 years, respectively. Improvement in New York Heart Association class compared with baseline was observed in 73.0% with moderate mismatch and 74.1% with severe mismatch. CONCLUSIONS: The Avalus (Medtronic, Minneapolis, Minn) bovine pericardial valve demonstrates good clinical and safety outcomes at 2 years. Hemodynamic performance shows mean gradients comparable to currently available bovine pericardial aortic valves. There was no clinical impact of moderate to severe mismatch at 2 years. Further follow-up is required to evaluate midterm to long-term clinical outcome.
引用
- Dagenais F, Moront MG, Brown WM, et al. Safety, efficacy, and hemodynamic performance of a stented bovine pericardial aortic valve bioprosthesis: Two-year analysis. J Thorac Cardiovasc Surg. 2019. PMID: 31590957. doi:10.1016/j.jtcvs.2019.07.132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。